Compositions for the Treatment and Prevention of Eyelid Swelling

Abstract

The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.

We claim: 
     
         1 . A topical pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one active agent selected from the group consisting of: an osmotically active agent, a vasoconstrictor, and an astringent agent, and combinations thereof, for the treatment and prevention of eyelid swelling in a subject. 
     
     
         2 . The composition of  claim 1 , wherein the active agent is an osmotically active agent selected from the group consisting of: a colloidal osmotic and a crystalloid osmotic. 
     
     
         3 . The composition of  claim 2 , wherein the crystalloid osmotic is selected from the group consisting of: sodium chloride, dextrose, glycerine, sucrose, mannitol, and sorbitol. 
     
     
         4 . The composition of  claim 3 , wherein the effective amount of the crystalloid osmotic is selected from the group consisting of: about 1% to about 10% sodium chloride, about 1% to about 10% dextrose, about 1% to about 20% glycerine, about 1% to about 20% mannitol, about 1% to about 95% sucrose, and about 1% to about 95% sorbitol. 
     
     
         5 . The composition of  claim 4 , wherein the effective amount of the crystalloid osmotic is about 1% to about 10% sodium chloride. 
     
     
         6 . The composition of  claim 2 , wherein the colloidal osmotic agent is selected from the group consisting of: hetastarch, pentastarch, dextran 70, dextran 40, albumin, and microcrystalline cellulose. 
     
     
         7 . The composition of  claim 6 , wherein the effective amount of the colloidal osmotic is selected from the group consisting of: about 1% to about 10% hetastarch, about 1% to about 20% pentastarch, about 1% to about 10% dextran 70, about 1% to about 10% dextran 40, about 1% to about 50% albumin, and about 1% to about 50% microcrystalline cellulose. 
     
     
         8 . The composition of  claim 1 , wherein the active agent is a vasoconstrictor is selected from the group consisting of: naphazoline, oxymetazoline, phenylephrine, and tetrahydrozoline, or other agent that decreases the diameter of blood vessels. 
     
     
         9 . The composition of  claim 8 , wherein the vasoconstrictor is naphazoline and the effective and the effective amount is about 0.01% to about 0.5%. 
     
     
         10 . The composition of  claim 1 , wherein the active agent is an astringent agent selected from the group consisting of witch hazel, zinc sulfate, silver sulfate, plant tannins, oak bark extract, pentagalloyl glucose, alum, burow's solution, black thorn extract, bird cherry extract and natural flavanoids. 
     
     
         11 . The composition of  claim 1 , wherein the active agent is one or more osmotically active agents and a vasoconstrictor. 
     
     
         12 . The composition of  claim 11 , wherein the osmotically active agent is sodium chloride and the vasoconstrictor is naphazoline. 
     
     
         13 . The composition of  claim 12 , wherein the effective amount of sodium chloride is about 1% to about 10%, and the effective amount of naphazoline is about 0.01% to about 0.5%. 
     
     
         14 . The composition of  claim 12 , wherein the one or more osmotically active agents are selected from sodium chloride, dextrose, sucrose, and mannitol, and wherein the vasoconstrictor is naphazoline. 
     
     
         15 . A method of treating and preventing eyelid swelling in a subject comprising: administering to the eye surface of the subject an effective amount of at least one active agent selected from the group consisting of: an osmotically active agent, a vasoconstrictor, and an astringent agent, and combinations thereof. 
     
     
         16 . The method of  claim 15 , wherein the active agent is an osmotically active agent selected from the group consisting of a crystalloid osmotic and a colloidal osmotic. 
     
     
         17 . The method of  claim 16 , wherein the crystalloid osmotic is selected from the group consisting of: sodium chloride, dextrose, glycerine, sucrose, mannitol, and sorbitol. 
     
     
         18 . The method of  claim 17 , wherein the effective amount of the crystalloid osmotic is selected from the group consisting of: about 1% to about 10% sodium chloride, about 1% to about 10% dextrose, about 1% to about 20% glycerine, about 1% to about 20% mannitol, about 1% to about 95% sucrose, and about 1% to about 95% sorbitol. 
     
     
         19 . The method of  claim 18 , wherein the effective amount of the crystalloid osmotic is about 1% to about 10% sodium chloride. 
     
     
         20 . The method of  claim 15 , wherein the colloidal osmotic agent is selected from the group consisting of: hetastarch, pentastarch, dextran 70, dextran 40, albumin, and microcrystalline cellulose. 
     
     
         21 . The method of  claim 20 , wherein the effective amount of the colloidal osmotic is selected from the group consisting of: about 1% to about 10% hetastarch, about 1% to about 20% pentastarch, about 1% to about 10% dextran 70, about 1% to about 10% dextran 40, about 1% to about 50% albumin, and about 1% to about 50% microcrystalline cellulose. 
     
     
         22 . The method of  claim 15 , wherein the active agent is a vasoconstrictor is selected from the group consisting of: naphazoline, oxymetazoline, phenylephrine, and tetrahydrozoline, or other agent that decreases the diameter of blood vessels. 
     
     
         23 . The method of  claim 22 , wherein the vasoconstrictor is naphazoline and the effective and the effective amount is about 0.01% to about 0.5%. 
     
     
         24 . The method of  claim 15 , wherein the active agent is an astringent agent selected from the group consisting of witch hazel, zinc sulfate, silver sulfate, plant tannins, oak bark extract, pentagalloyl glucose, alum, burow's solution, black thorn extract, bird cherry extract and natural flavanoids. 
     
     
         25 . The method of  claim 15 , wherein the active agent is an osmotically active agent and a vasoconstrictor. 
     
     
         26 . The method of  claim 25 , wherein the osmotically active agent is sodium chloride and the vasoconstrictor is naphazoline. 
     
     
         27 . The method of  claim 26 , wherein the effective amount of sodium chloride is about 1% to about 10%, and the effective amount of naphazoline is about 0.01% to about 0.5%. 
     
     
         28 . A kit comprising a pharmaceutical composition of  claim 1 .